I simply don't see Pfizer being able to convince their BOD to get involved with another inhaled insulin product. After a $2 billion write off for a failed attempt I think that would open barely healed wounds from the board and shareholders alike.

Pfizer lost an awful lot of credibility in the market from the exact doctors who they would need to prescribe Afrezza. The closer we get to FDA approval, the less I like the idea of splitting the profits with big pharma. I would almost rather see another massive dilution if we could raise the funds to get us safely through 6 months of a launch.